MediciNova, Inc.
MNOV
Rank in Stocks
#21158
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and... MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Share Price
$1.47
Last synced: 2026-11-09
Market Cap
$72.36M
Change (1 day)
0.68%
Change (1 year)
-4.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MediciNova, Inc. (MNOV)
Category
Healthcare
EPS for MediciNova, Inc. (MNOV)
EPS as of June 2026 TTM: $-0.22
According to MediciNova, Inc.'s latest financial reports, its current EPS (TTM) is $-0.22. At the end of 2025 the company had an EPS of $-0.24, a decrease compared to its 2024 EPS of $-0.23.
EPS history for MediciNova, Inc. from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.22 | -8.33% |
| 2025 | $-0.24 | 4.35% |
| 2024 | $-0.23 | 35.29% |
| 2023 | $-0.17 | -41.38% |
| 2022 | $-0.29 | 38.10% |
| 2021 | $-0.21 | -32.26% |
| 2020 | $-0.31 | 3.33% |
| 2019 | $-0.30 | -16.67% |
| 2018 | $-0.36 | 12.50% |
| 2017 | $-0.32 | -3.03% |
| 2016 | $-0.33 | 0.00% |
| 2015 | $-0.33 | -13.16% |
| 2014 | $-0.38 | 100.00% |
| 2013 | $-0.19 | -70.31% |
| 2012 | $-0.64 | -46.67% |
| 2011 | $-1.20 | -26.38% |
| 2010 | $-1.63 | -2.98% |
| 2009 | $-1.68 | -7.69% |
| 2008 | $-1.82 | -56.25% |
| 2007 | $-4.16 | 18.18% |
| 2006 | $-3.52 | 22.22% |
| 2005 | $-2.88 | -99.70% |
| 2004 | $-965.45 | 677.46% |
| 2003 | $-124.18 | -10.42% |
| 2002 | $-138.62 | 286.13% |
| 2001 | $-35.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -7,218.18% |
US
|
|
| $-7.07 | 3,113.64% |
US
|
|
| $-5.29 | 2,304.55% |
AU
|
|
| $12.88 | -5,954.59% |
BE
|
|
| $21.56 | -9,900.00% |
NL
|
Questions about MediciNova, Inc.'s earnings per share (EPS)
What is MediciNova, Inc.'s earnings per share (EPS)?
MediciNova, Inc.'s earnings per share (EPS) over the last twelve months is $-0.22, as of Jun 2026.
What was MediciNova, Inc.'s earnings per share (EPS) in 2025?
In 2025, MediciNova, Inc.'s earnings per share (EPS) was $-0.24, compared with $-0.23 in 2024.
How has MediciNova, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, MediciNova, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.17) and lowest in 2020 ($-0.31).
How does MediciNova, Inc.'s earnings per share (EPS) compare with similar companies?
MediciNova, Inc.'s earnings per share (EPS) ($-0.22) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.